Superficial radiation therapy provider Sensus Healthcare has signed a group purchasing agreement for brachytherapy products with Premier, effective August 1.
The new agreement offers special pricing and prearranged terms for Premier members to buy the SRT-100 superficial radiation therapy systems from Sensus. SRT is designed to deliver precise, calibrated, low-dose radiation to eradicate basal and squamous cell carcinomas, as well as the nonmalignant tumor cells that cause keloids -- a type of rare scar that can develop from a piercing or tattoo. Each treatment is virtually painless and does not involve cutting, bleeding, stitching, or anesthesia, according to the company.
Sensus SRT-100 has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of both nonmelanoma skin cancers and keloids.
